JP2016537410A5 - - Google Patents

Download PDF

Info

Publication number
JP2016537410A5
JP2016537410A5 JP2016551080A JP2016551080A JP2016537410A5 JP 2016537410 A5 JP2016537410 A5 JP 2016537410A5 JP 2016551080 A JP2016551080 A JP 2016551080A JP 2016551080 A JP2016551080 A JP 2016551080A JP 2016537410 A5 JP2016537410 A5 JP 2016537410A5
Authority
JP
Japan
Prior art keywords
composition according
composition
oligosaccharide
gos
management
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016551080A
Other languages
English (en)
Other versions
JP2016537410A (ja
JP6890972B2 (ja
Filing date
Publication date
Priority claimed from GBGB1319539.1A external-priority patent/GB201319539D0/en
Application filed filed Critical
Publication of JP2016537410A publication Critical patent/JP2016537410A/ja
Publication of JP2016537410A5 publication Critical patent/JP2016537410A5/ja
Application granted granted Critical
Publication of JP6890972B2 publication Critical patent/JP6890972B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (10)

  1. 微生物によって生成されたオリゴ糖を含むプレバイオティクス組成物であって、前記オリゴ糖が、所定のプロバイオティクス細菌株に選択的であること、および前記所定のプロバイオティクス細菌株によって逆酵素反応により生成することができることを特徴とし、
    前記所定のプロバイオティクス細胞株が、ラクトバチルス・プランタルム(Lactobacillus plantarum)を含み、前記酵素がβ−ガラクトシダーゼであり、前記オリゴ糖がガラクトオリゴ糖(GOS)を含み、前記GOSが、β1−4結合を含む、プレバイオティクス組成物。
  2. 被包されている、請求項1に記載の組成物。
  3. 身体の胃腸管環境を通過し、その機能的特性を保持できるようにするための賦形剤または担体化合物をさらに含む、請求項1からのいずれかに記載の組成物。
  4. 飲むことのできる液体の形態であり、かつ/または固体もしくは液体食料品と混合することができる、請求項1からのいずれか一項に記載の組成物。
  5. 品(medicament)として使用するための、請求項1からのいずれか一項に記載の組成物。
  6. 栄養補助食品として使用するための、請求項1から3のいずれか一項に記載の組成物。
  7. コレステロールの管理もしくは高コレステロールの処置に使用するための、請求項1からのいずれか一項に記載の組成物。
  8. メタボリック症候群の管理もしくは処置に使用するための、請求項1から3のいずれか一項に記載の組成物。
  9. 体重管理に使用するための、請求項1からのいずれか一項に記載の組成物。
  10. 糖尿病の処置に使用するための、請求項1から3のいずれか一項に記載の組成物。
JP2016551080A 2013-11-05 2014-11-05 組成物およびスクリーニング方法 Active JP6890972B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1319539.1A GB201319539D0 (en) 2013-11-05 2013-11-05 Composition & methods of screening
GB1319539.1 2013-11-05
PCT/GB2014/053303 WO2015067949A1 (en) 2013-11-05 2014-11-05 Composition & methods of screening

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019109634A Division JP2019206528A (ja) 2013-11-05 2019-06-12 組成物およびスクリーニング方法

Publications (3)

Publication Number Publication Date
JP2016537410A JP2016537410A (ja) 2016-12-01
JP2016537410A5 true JP2016537410A5 (ja) 2018-06-14
JP6890972B2 JP6890972B2 (ja) 2021-06-18

Family

ID=49767702

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016551080A Active JP6890972B2 (ja) 2013-11-05 2014-11-05 組成物およびスクリーニング方法
JP2019109634A Pending JP2019206528A (ja) 2013-11-05 2019-06-12 組成物およびスクリーニング方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019109634A Pending JP2019206528A (ja) 2013-11-05 2019-06-12 組成物およびスクリーニング方法

Country Status (7)

Country Link
US (2) US9913857B2 (ja)
EP (2) EP3065572B1 (ja)
JP (2) JP6890972B2 (ja)
AU (2) AU2014345344B2 (ja)
CA (2) CA2929815C (ja)
GB (2) GB201319539D0 (ja)
WO (1) WO2015067949A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105407728A (zh) 2013-07-21 2016-03-16 霍勒拜欧姆公司 用于微生物组表征、监测和治疗的方法和系统
AU2015341571A1 (en) * 2013-11-05 2017-05-18 Optibiotix Limited Prebiotic composition and its method of production
GB201319531D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
GB201319539D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
WO2016070151A1 (en) 2014-10-31 2016-05-06 Whole Biome. Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
GB201509023D0 (en) * 2015-05-27 2015-07-08 Optibiotix Ltd Compositions and methods of production thereof
GB201509021D0 (en) * 2015-05-27 2015-07-08 Optibiotix Ltd Methods of screening
EP3491382A4 (en) * 2016-07-29 2020-04-08 Isothrive LLC OPTIMIZED INDIVIDUALIZED PREBIOTIC COMPOSITIONS
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス, インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
EP4056052A1 (en) * 2021-03-12 2022-09-14 Biogaia AB Gos pre-conditioning l. reuteri and gos in final formulation
EP4056053A1 (en) * 2021-03-12 2022-09-14 Biogaia AB Pre-conditioning of l. reuteri
WO2024013211A1 (en) * 2022-07-12 2024-01-18 Novozymes A/S Method for providing relief from lactose induced abdominal discomfort

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69600525T2 (de) 1996-12-23 1998-12-10 Sitia Yomo Spa Lyophilisierte, lebende Bakerien enthaltende Nahrungszusammensetzung
GB0303716D0 (en) * 2003-02-18 2003-03-19 Mars Uk Ltd Food product and process
CA2652517A1 (en) 2006-06-13 2007-12-21 Nestec S.A. Prevention and treatment of otitis media with non-pathogenic bacterial strains
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
WO2010060722A1 (en) 2008-11-03 2010-06-03 Nestec S.A. A nutritional composition comprising probiotics and improving sleep patterns
EP2216036A1 (en) 2009-02-10 2010-08-11 Nestec S.A. Lactobacillus rhamnosus NCC4007, a probiotic mixture and weight control
PL2419114T5 (pl) * 2009-05-01 2019-09-30 Uas Laboratories Llc Kompozycje bakteryjne do profilaktyki i leczenia choroby degeneracyjnej
US20110117629A1 (en) * 2009-11-19 2011-05-19 Family Medicine Interantional Co., Ltd. Lactobacillus plantarum bb9 capable of adhering to gastrointestinal tract and cholesterol removal
CN102985105B (zh) 2010-01-19 2016-03-09 雅培制药有限公司 包含合生元的营养配方
US20120263696A1 (en) 2011-04-14 2012-10-18 Stefan Roos Indirect Substrates for Microorganisms Metabolizing 1,2-Propanediol
GB201319539D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening

Similar Documents

Publication Publication Date Title
JP2016537410A5 (ja)
Le Doare et al. Mother’s milk: a purposeful contribution to the development of the infant microbiota and immunity
Indira et al. Bioactive molecules of probiotic bacteria and their mechanism of action: a review
NZ601141A (en) Nutritional formulas containing synbiotics
NZ612386A (en) Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
MY187609A (en) Human milk oligosaccharides to ameliorate symptoms of stress
JP2012520325A5 (ja)
PH12016501953A1 (en) Pediatric nutritional composition with human milk oligosaccharides, prebiotics and probiotics
WO2012024638A3 (en) Compositions and methods for treating obesity by characterizing and restoring mammalian bacterial microbiota
JP2015523321A5 (ja)
Wang et al. Characteristics of probiotic preparations and their applications
Kvakova et al. Co-encapsulated synbiotics and immobilized probiotics in human health and gut Microbiota modulation
WO2010146568A3 (en) Bifidobacteria for treating diabetes and related conditions
JP2017537156A5 (ja)
JP2016529309A5 (ja)
WO2014006261A3 (es) Micropartículas para encapsulación de probióticos, su obtención y usos
CL2008001993A1 (es) Uso de bacterias probioticas lactobacillus y bifidobacterium en la preparacion de una composicion para normalizar la concentracion de glucosa plasmatica, aumentar la respuesta a insulina y prevenir la diabetes gestacional.
MY158816A (en) Probiotics for reduction of risk of obesity
MX2009009442A (es) Probioticos para mejorar la microbiota intestinal.
JP2013139462A5 (ja)
JP2013177448A5 (ja)
MX2013002171A (es) Producto simbiotico.
WO2009112361A3 (en) Synbiotic mixture
JP2019508486A5 (ja)
Gulliver et al. the future of microbiome‐based therapeutics